Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncolys BioPharmaTSE:4588 -0.83%40 Altman Z-Score is 46.33 as of Jul. 14, 2026, which is 385% above its 10-year median of 9.55. GuruFocus rates TSE:4588 with a GF Score™ of 40/100 and a GF Value™ of 円363.33 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 928 Biotechnology companies, Oncolys BioPharma ranks better than 98.17% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 80.87 is strong.
Oncolys BioPharma has a Altman Z-Score of 46.33, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Oncolys BioPharma's Altman Z-Score or its related term are showing as below:
TSE:4588'
s Altman Z-Score Range Over the Past 10 Years
Min: 3.1 Med: 9.55 Max: 80.87
Current: 80.87
During the past 13 years, Oncolys BioPharma's highest Altman Z-Score was 80.87. The lowest was 3.10. And the median was 9.55.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Oncolys BioPharma Altman Z-Score Related Terms
Oncolys BioPharma Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Oncolys BioPharma's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4588 vs VRTX, REGN, ALNY: Altman Z-Score Comparison
For the Biotechnology subindustry, Oncolys BioPharma's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncolys BioPharma Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncolys BioPharma's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Oncolys BioPharma's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Oncolys BioPharma's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.7947
+
1.4
*
-0.546
+
3.3
*
-0.3798
+
0.6
*
78.9755
+
1.0
*
0.007
=
46.33
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Oncolys BioPharma (TSE:4588) has a Altman Z-Score of 46.33 as of Jul. 14, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Oncolys BioPharma and its competitors. This is 385% above median its historical median of 9.55. Over the past decade, Oncolys BioPharma's Altman Z-Score has ranged from 3.10 to 80.87. According to the industry distribution chart, Oncolys BioPharma ranks #17 out of 928 companies in the Biotechnology industry, placing it in the top 1.8%.
Is Oncolys BioPharma's Altman Z-Score too high?
Oncolys BioPharma's current Altman Z-Score of 46.33 is 385% above median its 10-year median of 9.55. Over the past 10 years, this metric has ranged from a low of 3.10 to a high of 80.87. The Biotechnology industry median Altman Z-Score is 2.69. Oncolys BioPharma's value of 46.33 is 1622.3% above this industry median. Based on the distribution chart, Oncolys BioPharma ranks #17 out of 928 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Oncolys BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncolys BioPharma's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncolys BioPharma ranks #17 out of 928 companies for Altman Z-Score. This places Oncolys BioPharma in the top 2% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.69. Oncolys BioPharma's value of 46.33 is 1622.3% above this benchmark. Historically, Oncolys BioPharma's own Altman Z-Score has ranged from 3.10 to 80.87 over the past decade. While the company's 10-year median is 9.55 vs. the industry median of 2.69, Oncolys BioPharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.69, based on 928 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncolys BioPharma's current Altman Z-Score of 46.33 is 1622.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Oncolys BioPharma and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncolys BioPharma's current Altman Z-Score is 46.33, which is 385% above median its own 10-year median of 9.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolys BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Oncolys BioPharma (TSE:4588) is currently considered Significantly Overvalued. The stock's GF Value™ is 円363.33, compared to a current price of 円2,501.00 — trading 588.4% above its estimated fair value. The current Altman Z-Score is 46.33, which is 385% above median its 10-year median of 9.55 and 1622.3% above the Biotechnology industry median of 2.69. Oncolys BioPharma's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Oncolys BioPharma (TSE:4588), the current Altman Z-Score is 46.33 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncolys BioPharma (TSE:4588) Overvalued in 2026?
Based on GuruFocus' analysis, Oncolys BioPharma stock appears to be overvalued.
The current stock price of 円2,501.00 is trading 588.4% above its estimated GF Value™ of 円363.33.
GuruFocus considers Oncolys BioPharma to be Significantly Overvalued.
Key valuation signals for TSE:4588:
Altman Z-Score: 46.33 (385% above median its 10-year median of 9.55)
GF Value™: 円363.33 vs. price of 円2,501.00 (588.4% above fair value)
Industry Position: 1622.3% above the Biotechnology median (#17 of 928)
No single metric tells the full story. See the TSE:4588 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncolys BioPharma Inc develops pharmaceutical products. The company is a biopharmaceutical company focused on developing therapies for cancer treatment. Their product pipeline includes various drug candidates such as Telomelysin (OBP-301) and OBP-702, aimed at addressing unmet medical needs in oncology. The company targets healthcare providers and institutions involved in cancer care and research.
40GF Score
Get the complete analysis for TSE:4588
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4588 has been successfully added to your 
